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reported by Jansen et al4 in 3-year-old children. Research sug-
gests that impaired neuromotor development precedes schizo-
phrenia onset, although most children with impaired neuromo-
tor functioning do not develop schizophrenia.2 In contrast,
children who later met criteria for BD exhibited a higher level of
motor performance during childhood than controls.1 Our results
highlight that the genetic predisposition for schizophrenia
covaries with motor deficits observable during infancy in a
community-based sample. Given that the prevalence of schizo-
phrenia is low, these early features represent indices of liability
rather than precursors of the disorder.
This study has certain limitations. Genetic pleiotropy or
early environmental factors could also explain the association.1
Selective nonresponse to neuromotor assessment could bias
the analysis. The power of the BD GWAS might have been in-
sufficient to detect associations between BD PRS and neuro-
motor development. Despite limitations, this study has sev-
eral strengths, including an objective and prospectively
assessed measure of neuromotor development in a large ho-
mogenous sample of infants.
To our knowledge, this is the first evidence that genetic
liability for schizophrenia may covary with altered neuromo-
tor development in infancy. Future research will show whether
early neuromotor development can support early screening of
susceptible groups possibly defined by genetic risk.
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Assessment of Symptom Network Density
as a Prognostic Marker of Treatment Response
in Adolescent Depression
One in 4 adolescents with depression does not respond favor-
ably to treatment.1 Prognostic markers to identify this nonre-
sponder group are lacking and urgently needed.2 It has been
suggested that the network structure of depressive symp-
toms (ie, group-level covariance or connectivity between symp-
toms) may be informative in this regard.3 Intuitively, one may
expect that more densely connected networks would be more
inclined to result in negative spirals (eg, sleeplessness causes
an individual to be too tired to go out, which leads to a lack of
friends, resulting in sadness) and therefore more liable to non-
response. An influential naturalistic study by van Borkulo et
al published in JAMA Psychiatry3 reported that adult patients
with depression who continue to experience problems in sub-
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sequent years have more densely connected networks at base-
line than patients who later recover. Here, we performed a con-
ceptual replication of that study in adolescents with depression
who participated in a psychological treatment trial. We tested
whether network characteristics at baseline were prognostic
for long-term outcomes.1
Methods | Patients with depression completed the 33-item
Mood and Feelings Questionnaire (MFQ) prior to treatment,
with regular additional assessments up to 12 months after
the end of treatment (ie, mean [SD], 22 [4.7] months after
baseline assessment). The MFQ assesses recent self-reported
depressive symptoms on a 4-point scale (never, sometimes,
often, and always), with total scores ranging from 0 to 66
(higher scores indicate more severe depressive symptoms).4
In accordance with van Borkulo et al,3 11 items optimally
representing DSM-5 symptoms of depression were selected
for use in the present study conducted from June 29, 2010,
to January 17, 2013, with data analyses performed from Feb-
ruary 1 to June 25, 2017. The study was approved by the
Cambridgeshire Research Ethics Committee and local
National Health Service provider trusts. All patients and par-
ents gave written informed consent.
To derive 2 equally sized groups, relatively good and poor
responders were differentiated by the median percentage
change between baseline and final follow-up of the MFQ sum-
mary score (median [interquartile range], −66% [41.2%]). Base-
line regularized partial correlation matrices were estimated
based on Spearman correlation coefficients.5 From those, the
weighted sum of all absolute connections in the network (net-
work density) as well as in each node (node strength) was de-
rived. Parameters were compared using permutation testing
(global α = .05; adjusted α per node per item, .05/11 = .005;
1-sided).6 All analyses were performed using R, version 3.2.4
(The R Foundation), with the qgraph package, version 1.3.5.
Results | The cohort consisted of 465 adolescents with
depression (349 [75.1%] were girls; aged 11-17 years). Good
responders had higher mean (SD) MFQ summary scores at
baseline (47.5 [9.2] vs 44.3 [11.6]; P = .006) and higher mean
(SD) levels of suicidality (1.25 [0.9] vs 1.00 [0.9]; P < .001)
compared with poor responders. Although global network
strength was higher in poor responders, the difference was
not significant (good responders, 3.6; poor, 4.3; P = .15;
Figure 1). There were no differences in local node strength
except for that of “concentration problems,” which at the
uncorrected α level was more connected to the other nodes
in the poor responders than in the good responders (good
responders, 1.1; poor responders, 2.0; P = .02; Figure 2). Sen-
sitivity analyses indicated similar findings when treatment
response was defined as below clinical threshold (ie, MFQ
score <27) at the final follow-up.4
Discussion | Applying the same statistical methods as those
used in the study by van Borkulo et al,3 which had a simi-
larly sized sample of adults with depression followed up
naturalistically, we found no significant association between
higher network strength and poorer outcomes. That the
direction of the association in our study was consistent with
the results of the previous study, however, indicates that
further investigation of the validity of network strength as a
prognostic marker is warranted. There were 2 important
methodological differences between the studies. First, the
previous one was a naturalistic cohort study, whereas here
we evaluated treatment outcomes. Stronger symptom net-
works may be prognostic of depression persistence in natu-
ralistic settings but not when symptoms (and perhaps net-
works) are actively being challenged. Second, network
density may not have equal prognostic value in adult and
adolescent groups. For instance, denser networks may be a
consequence and a behavioral marker of longer illness dura-
tion or recurrent episodes but have no such signature in
first-episode depression in adolescents. Unfortunately, this
hypothesis cannot be tested within the current sample of
adolescents with depression, most of whom were experienc-
ing their first episode.






















Good respondersA Poor respondersB
Blue lines represent positive
connections; red lines, negative
connections; and thicker lines,
stronger connections. For the
symptom (node) abbreviations,
agi indicates psychomotor agitation;
con, concentration problems;
dep, feeling sad/depressed; ene, loss
of energy; gui, guilt/worthlessness;
hyp, hypersomnia; ins, insomnia;
int, loss of interest/pleasure;
ret, psychomotor retardation;
sui, suicidal ideation; and wap, weight
or appetite change.
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With network analyses taking an astonishing flight in psy-
chiatry, we recommend cautious application of group-level net-
work density as a prognostic marker. Crucial steps to be taken
by the field include further replication studies as well as in-
depth psychometric evaluation of the reliability and clinical
correlates of network parameters.
Lizanne Schweren, PhD
Claudia D. van Borkulo, MSc
Eiko Fried, PhD
Ian M. Goodyer, MD
Author Affiliations: Department of Psychiatry, University of Cambridge,
Cambridge, United Kingdom (Schweren, Goodyer); Department of Psychology,
University of Amsterdam, Amsterdam, the Netherlands (van Borkulo, Fried).
Corresponding Author: Lizanne Schweren, PhD, Department of Psychiatry,
University of Cambridge, 18b Trumpington Rd, Douglas House, Cambridge CB2
8AH, United Kingdom (ljs82@medschl.cam.ac.uk).
Accepted for Publication: October 3, 2017.
Published Online: November 29, 2017. doi:10.1001/jamapsychiatry.2017.3561
Author Contributions: Drs Schweren and Fried had full access to all of the data
in the study and take responsibility for the integrity of the data and the accuracy
of the data analysis.
Study concept and design: Schweren, van Borkulo, Goodyer.
Acquisition, analysis, or interpretation of data: All authors.
Drafting of the manuscript: Schweren, Goodyer.
Critical revision of the manuscript for important intellectual content: All authors.
Statistical analysis: All authors.
Obtained funding: Goodyer.
Administrative, technical, or material support: Schweren, Goodyer.
Study Supervision: Fried.
Conflict of Interest Disclosures: Dr Goodyer reported serving as a paid
consultant for Lundbeck and licensing the Brief Psychosocial Intervention to
Lundbeck for use in a clinical trial. No other disclosures were reported.
Funding/Support: The Improving Mood with Psychoanalytic Psychotherapy
and Cognitive Behaviour Therapy (IMPACT) trial was funded by the Health
Technology Assessment program of the National Institute for Health Research
(06/05/01). Dr Schweren is a research associate funded by the Friends of
Peterhouse. Drs Fried and van Borkulo are funded by Consolidator Grant
647209 from the European Research Council.
Role of the Funder/Sponsor: The funding sources had no role in the design and
conduct of the study; collection, management, analysis, and interpretation of
the data; preparation, review, or approval of the manuscript; or the decision to
submit the manuscript for publication.
Additional Contributions: We thank all members of the IMPACT consortium.
1. Goodyer IM, Reynolds S, Barrett B, et al. Cognitive behavioural therapy and
short-term psychoanalytical psychotherapy versus a brief psychosocial
intervention in adolescents with unipolar major depressive disorder (IMPACT):
a multicentre, pragmatic, observer-blind, randomised controlled superiority
trial. Lancet Psychiatry. 2017;4(2):109-119.
2. Nilsen TS, Eisemann M, Kvernmo S. Predictors and moderators of outcome in
child and adolescent anxiety and depression: a systematic review of
psychological treatment studies. Eur Child Adolesc Psychiatry. 2013;22(2):69-87.
3. van Borkulo C, Boschloo L, Borsboom D, Penninx BWJH, Waldorp LJ,
Schoevers RA. Association of symptom network structure with the course of
[corrected] depression. JAMA Psychiatry. 2015;72(12):1219-1226.
4. Daviss WB, Birmaher B, Melhem NA, Axelson DA, Michaels SM, Brent DA.
Criterion validity of the Mood and Feelings Questionnaire for depressive
episodes in clinic and non-clinic subjects. J Child Psychol Psychiatry. 2006;47
(9):927-934.
5. Epskamp S, Cramer AOJ, Waldorp LJ, Schmittmann VD, Borsboom D.
Qgraph: network visualizations of relationships in psychometric data. J Stat Soft.
2012;48(4):1-18.
6. van Borkulo CD, Waldorp LJ, Boschloo L, et al. Comparing network
structures on three aspects: a permutation test. ResearchGate. Published March
2017. Accessed May 4, 2017. doi:10.13140/RG.2.2.29455.38569
Pediatric Use of Antipsychotic Medications
Before and After Medicaid Peer Review
Implementation
In response to the growing cardiometabolic safety concerns
about the use of atypical antipsychotic (AAP) medications in
children,1,2 several state Medicaid agencies have adopted a
novel, more clinically nuanced and individualized approach
to reviewing the appropriateness of AAP use, namely, peer re-
view prior authorization (PA) policies.3 Physicians must re-
ceive preapproval through contracted clinicians (peer review-
ers) to prescribe AAPs to certain-aged children. We assessed
the effect of peer review PA policies on AAP use among Med-
icaid-insured youth according to age restriction criteria.
Figure 2. Differences in Total Mood and Feelings Questionnaire (MFQ)
Mean Score, SD of the Mean Score, and Node Strength by Symptom




















































Red boxes outline statistically significant differences. Symptom (node)
abbreviations are defined in the caption to Figure 1.
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